{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:35:06Z","timestamp":1788831306961,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72804052"],"award-info":[{"award-number":["72804052"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Antipsychotic drugs are the main therapy for schizophrenia and have been widely used in mental disorder fields. However, the research on the safety of antipsychotic drugs in the real-world is rare. The purpose of this research is to evaluate the safety of antipsychotic drugs based on real-world data.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> ADR reports collected by the Henan Adverse Drug Reaction Monitoring Center from 2016 to 2020 were analyzed. We described the safety of antipsychotic drugs by descriptive analysis and four signal mining methods. Meanwhile, the risk factors for serious adverse reactions of antipsychotics were identified.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 3363 ADR reports related to antipsychotics were included. We found that the number of adverse drug reaction reports and the proportion of serious adverse reactions have increased year by year from 2016 to 2020. Most adverse drug reactions occurred within 3\u00a0months after taking the medicine. The symptoms caused by typical antipsychotics and atypical antipsychotics were different and dyskinesia was more common in typical antipsychotics. Most patients improved or recovered after treatment or intervention while only one patient had sequelae. Low-level hospitals, psychiatric hospitals, youth, and old age could increase the risk of serious adverse reactions. Four off-label signals were found through signal mining, including amisulpride-pollakiuria, ziprasidone-dyspnoea, quetiapine-urinary incontinence, olanzapine-hepatic function abnormal.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> We found that most ADRs occurred within 3\u00a0months after taking the medicine, so close observation was required for patients during the first 3\u00a0months of treatment. The ADRs of antipsychotics involved multiple organ-system damages but were not serious. It might be recommended to take alternative drugs after a serious ADR occurred. The symptoms caused by typical APDs and atypical APDs were different. For patients with typical APDs, dyskinesia was more common and should be given special attention. Statistics showed that low-level hospitals, psychiatric hospitals, youth, and old age were risk factors for serious ADRs. The four off-label signals obtained by signal mining should be paid special attention, including amisulpride-pollakiuria, ziprasidone-dyspnoea, quetiapine-urinary incontinence, and olanzapine-hepatic function abnormal.<\/jats:p>","DOI":"10.3389\/fphar.2022.848472","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:37:19Z","timestamp":1646818639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety Profile of Antipsychotic Drugs: Analysis Based on a Provincial Spontaneous Reporting Systems Database"],"prefix":"10.3389","volume":"13","author":[{"given":"Kangyuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanchun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15690","DOI":"10.5281\/zenodo.2054040","article-title":"Antipsychotics- Classification, Uses, and Adverse Effects","volume":"5","author":"Al Hattab","year":"2018","journal-title":"Indo Am. J. Pharm. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.psc.2016.01.008","article-title":"Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play","volume":"39","author":"Ames","year":"2016","journal-title":"Psychiatr. Clin. North. Am."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian Neural Network Method for Adverse Drug Reaction Signal Generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global Epidemiology and Burden of Schizophrenia: Findings from the Global Burden of Disease Study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull."},{"key":"B5","first-page":"139","article-title":"Characteristics of Unrecognised Bipolar Disorder in Patients Treated for Major Depressive Disorder in China: General versus Psychiatric Hospitals","volume":"23","author":"Chen","year":"2013","journal-title":"East. Asian Arch. Psychiatry"},{"key":"B6","unstructured":"Guiding Principles for the Establishment and Planning of Medical Institutions (2016-2020)2016"},{"key":"B7","unstructured":"The Reporting and Monitoring Administration Measure on ADR [Online]2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4088\/jcp.0808e24","article-title":"Assessing and Maximizing the Safety and Tolerability of Antipsychotics Used in the Treatment of Children and Adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and Cardiovascular Adverse Effects Associated with Antipsychotic Drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40263-015-0269-4","article-title":"The Use of Continuous Treatment versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics","volume":"29","author":"De Hert","year":"2015","journal-title":"Cns Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/s0140-6736(00)02799-9","article-title":"Adverse Drug Reactions: Definitions, Diagnosis, and Management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e5154","DOI":"10.5812\/ijpbs.5154","article-title":"Quetiapine-Induced Enuresis: Two Case Reports","volume":"11","author":"Elyasi","year":"2017","journal-title":"Iran J. Psychiatry Behav. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of Proportional Reporting Ratios (PRRs) for Signal Generation from Spontaneous Adverse Drug Reaction Reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1055\/s-2003-39044","article-title":"Uncommon Side Effects Associated with Olanzapine. A Case Report","volume":"36","author":"Farooque","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.1351","article-title":"Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making","volume":"105","author":"Franklin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","article-title":"Relapse Prevention in First-Episode Schizophrenia-Mmaintenance vs Intermittent Drug Treatment with Prodrome-Based Early Intervention: Results of a Randomized Controlled Trial within the German Research Network on Schizophrenia","volume":"72","author":"Gaebel","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/acps.13359","article-title":"A Systematic Review and Pooled, Patient-Level Analysis of Predictors of Mortality in Neuroleptic Malignant Syndrome","volume":"144","author":"Guinart","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"B18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/cnd.0000000000000233","article-title":"Toxic Myopathy Due to Antidopaminergic Medication without Neuroleptic Malignant Syndrome","volume":"20","author":"Harada","year":"2018","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2215-0366(18)30511-X","article-title":"Prevalence of Mental Disorders in China: a Cross-Sectional Epidemiological Study","volume":"6","author":"Huang","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.toxlet.2019.08.013","article-title":"Up-regulation of Hepatic Fatty Acid Transporters and Inhibition\/down-Regulation of Hepatic OCTN2 Contribute to Olanzapine-Induced Liver Steatosis","volume":"316","author":"Jiang","year":"2019","journal-title":"Toxicol. Lett."},{"key":"B23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/ndt.S147124","article-title":"Safety and Effectiveness of Rapid-Acting Intra-muscular Olanzapine for Agitation Associated with Schizophrenia - Japan Postmarketing Surveillance Study","volume":"14","author":"Katagiri","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-015-0015-6","article-title":"Hyperglycemic Adverse Events Following Antipsychotic Drug Administration in Spontaneous Adverse Event Reports","volume":"1","author":"Kato","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"key":"B25","first-page":"1","article-title":"Effect Evaluation of Adverse Drug Reactions Monitoring Based on Chinese Hospital Pharmacovigilance System","author":"Lirong","year":"2021","journal-title":"Chin. J. Pharmacovigilance"},{"key":"B26","first-page":"394","article-title":"Possible Olanzapine-Induced Hepatotoxicity in a Young Chinese Patient","volume":"15","author":"Lui","year":"2009","journal-title":"Hong Kong Med. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/acps.12445","article-title":"Weight Gain and Obesity in Schizophrenia: Epidemiology, Pathobiology, and Management","volume":"132","author":"Manu","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"key":"B28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/YIC.0b013e3280117fff","article-title":"Alopecia Associated with Quetiapine","volume":"22","author":"McLean","year":"2007","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s002130050018","article-title":"An Atypical Compound by Any Other Name Is Still a","volume":"148","author":"Meltzer","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"B30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on Typical and Atypical Antipsychotic Drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1080\/15622970802045070","article-title":"Urinary Incontinence Associated with Amisulpride","volume":"10","author":"Mendhekar","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e3437","DOI":"10.1097\/md.0000000000003437","article-title":"Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa","volume":"95","author":"Mouton","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B33","first-page":"617","article-title":"Adverse Effects of Antipsychotic Medications","volume":"81","author":"Muench","year":"2010","journal-title":"Am. Fam. Physician"},{"key":"B34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ajp.2017.07.010","article-title":"\u201cUrinary Incontinence Secondary to Amisulpride Use-A Report\u201d","volume":"29","author":"Niranjan","year":"2017","journal-title":"Asian J. Psychiatr."},{"key":"B35","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/s0167-9473(99)00114-0","article-title":"Bayesian Neural Networks with Confidence Estimations Applied to Data Mining","volume":"34","author":"Orre","year":"2000","journal-title":"Comput. Stat. Data Anal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/01.pra.0000452568.92449.3f","article-title":"Olanzapine-Induced Triglyceride and Aminotransferase Elevations without Weight Gain or Hyperglycemia Normalized after Switching to Aripiprazole","volume":"20","author":"Pawelczyk","year":"2014","journal-title":"J. Psychiatr. Pract."},{"key":"B36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A Comparison of Risperidone-Induced Weight Gain across the Age Span","volume":"24","author":"Safer","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s40264-017-0560-z","article-title":"Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database","volume":"40","author":"Sakai","year":"2017","journal-title":"Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/schbul\/sbt096","article-title":"Intermittent Drug Techniques for Schizophrenia","volume":"39","author":"Sampson","year":"2013","journal-title":"Schizophr Bull."},{"key":"B39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-week Trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-Affective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study","volume":"165","author":"Sikich","year":"2008","journal-title":"Ajp"},{"key":"B41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.genhosppsych.2007.08.012","article-title":"Ziprasidone-induced Tardive Laryngeal Dystonia: a Case Report","volume":"30","author":"Tsai","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","article-title":"Detecting Drug-Drug Interactions Using a Database for Spontaneous Adverse Drug Reactions: an Example with Diuretics and Non-steroidal Anti-inflammatory Drugs","volume":"56","author":"van Puijenbroek","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","article-title":"Signalling Possible Drug-Drug Interactions in a Spontaneous Reporting System: Delay of Withdrawal Bleeding during Concomitant Use of Oral Contraceptives and Itraconazole","volume":"47","author":"van Puijenbroek","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/s0140-6736(17)32154-2","article-title":"Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990-2016: a Systematic Analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Vos","year":"2017","journal-title":"Lancet"},{"key":"B46","unstructured":"ATC Classification index with DDDs [Online]. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology2021"},{"key":"B47","unstructured":"WHO Pharmaceuticals Newsletter No.5, 20192019"},{"key":"B48","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\"First Do No harm.\" A Systematic Review of the Prevalence and Management of Antipsychotic Adverse effectsA Systematic Review of the Prevalence and Management of Antipsychotic Adverse Effects","volume":"29","author":"Young","year":"2015","journal-title":"J. Psychopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.848472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T09:37:26Z","timestamp":1646818646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.848472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":48,"alternative-id":["10.3389\/fphar.2022.848472"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.848472","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,9]]},"article-number":"848472"}}